Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focused on innovative breast cancer treatments and prevention, has appointed CORE IR as its investor relations and public relations partner. This announcement, made on September 17, 2025, emphasizes Atossa's goal to enhance its communications with the investment community and engage more effectively with both institutional and retail shareholders.

Dr. Steven Quay, the company’s Chairman and CEO, expressed optimism about this collaboration, highlighting its role in driving stakeholder value and increasing market visibility. He noted that CORE IR's expertise would help the firm articulate its value proposition more clearly to potential investors. CORE IR, known for its strategic guidance for both emerging and established companies, will provide a comprehensive range of services, including strategic messaging, investor targeting, and non-deal roadshow support.

Scott Gordon, Co-Founder and President of CORE IR, shared enthusiasm about partnering with Atossa, recognizing the company's commitment to pioneering therapies in breast cancer treatment and prevention. CORE IR aims to enhance Atossa's engagement with the investment community, aligning with the company's mission to improve breast cancer outcomes through innovative science.

Atossa Therapeutics is advancing its lead product candidate, (Z)-endoxifen, a potent selective estrogen receptor modulator designed for various breast cancer applications, including risk-reduction and treatment across different stages. The company is dedicated to advancing clinical research to benefit patients while ensuring sustainable value for its shareholders. For additional information about Atossa Therapeutics and its initiatives, stakeholders can visit their website at atossatherapeutics.com.

Atossa Therapeutics' recent appointment of CORE IR as its investor relations advisor represents a strategic move that may enhance its market presence and drive shareholder value. As a clinical-stage biopharmaceutical company focused on innovative breast cancer therapies, strengthening communications and investor engagement is critical for Atossa as it seeks to advance its pipeline and improve patient outcomes.

By partnering with CORE IR, Atossa is positioning itself to more effectively communicate its value proposition to both institutional and retail investors. This collaboration is timely; the biopharmaceutical sector is highly competitive and investor sentiment can rapidly shift based on perceptions of a company’s potential and clinical progress. The comprehensive suite of services that CORE IR will provide—including strategic messaging, investor targeting, non-deal roadshow support, and enhanced communication strategies—could help attract new investors and retain current shareholders.

Investors should consider the implications of this partnership regarding Atossa's commitment to transparency and proactive engagement, particularly as it progresses through critical clinical trials for its lead candidate, (Z)-endoxifen. Given the potential of this compound to target various stages of breast cancer, there is a significant opportunity for Atossa to capture market interest, leading to potential share price appreciation.

For investors looking at Atossa (Nasdaq: ATOS), this development could be a catalyst for increased market visibility and institutional interest. However, it is essential to maintain a cautious approach. Investors should conduct thorough due diligence, considering the company's clinical milestones, financial health, and market conditions. Engaging with Atossa's communications will be crucial as the company advances its innovative treatments and seeks to solidify its place in the biopharmaceutical landscape. Overall, this partnership might indicate a pivotal moment for Atossa, enhancing its capability to navigate the complexities of investor relations within a dynamic healthcare market.